A second clinical trial uses CRISPR-Cas9 to disrupt the kallikrein protein to counteract altered levels of the peptide hormone bradykinin in patients with hereditary angioedema, which results in severe swelling of the limbs and abdomen [131]. The gene discussed is KLK4; the disease is hereditary angioedema.